ClinicalTrials.gg
CompletedNCT05642312MeerkatUpdated Nov 21, 2025

A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema

A Phase 3 interventional study of Vamikibart and Sham in Uveitic Macular Edema, sponsored by Hoffmann-La Roche. Completed at 77 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Nov 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Macular Edema by Hoffmann-La Roche — 1 open to participants now, 5 under way, 1 of them phase 3. Macular Edema · Hoffmann-La Roche.

Enrollment
15th of 25
245 · median 377
Started
2023
with 1 other
Phase 3
14 of 28
none open now
Registered
21st of 28
by date

Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 15th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2023, is one of 14 in phase 3, and was the 21st registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 28 studies in Macular Edema by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Macular Edema by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

03

Conditions studied

  • Uveitic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants: Agreement to remain abstinent (refrain from heterosexual intercourse) or use as defined by the protocol
  • Diagnosis of macular edema associated with non-infectious uveitis (NIU)
  • Diagnosis of active or inactive, acute, or chronic NIU of any etiology and of any anatomical type (anterior, intermediate, posterior, panuveitis)
  • BCVA letter score of 73 to 19 letters (inclusive) on Early Treatment Diabetic Retinopathy Study (EDTRS)-like charts

Exclusion criteria

Exclusion Criteria:

  • Evidence of active or latent syphilis infection
  • Evidence of active or latent tuberculosis infection and/or positive tuberculosis assay, or previous or current diagnosis
  • Serious acute or chronic medical or psychiatric illness
  • History of major ocular and non-ocular surgical procedures
  • Uncontrolled IOP or glaucoma or chronic hypotony
  • Any anatomical changes or media opacity in the study eye preventing evaluation of retina, vitreous, and capture of study images
  • Prior use of IVT biologics including anti-VEGFs less than 2-4 months prior to Day 1; received IVT Methotrexate within 4 months prior to Day 1
  • Prior macular laser therapy, cataract surgery within 6 months and laser capsulotomy within 3 months of Day 1
  • Topical and/or topical NSAID > 3 drops per day in the 14 days prior to Day 1 (D1); intraocular or periocular corticosteroid injections in the 2 months prior to D1; subconjunctival corticosteroid injection within 1 month prior to Day 1; an OZURDEX implant in the 4 months prior to D1; YUTIQ, RETISERT or ILUVIEN implant in the 3 years prior to D1
  • Diagnosis of macular edema due to any cause other than NIU
  • Any major ocular conditions that may require medical or surgical intervention during the study period to prevent vision loss
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
245 participants (actual)

Study arms

  • Experimental
    Arm A

    Participants will receive 4 high-dose vamikibart intravitreal (IVT) injections every 4 weeks (Q4W) to Week 12, followed by as-needed (PRN) dosing from Week 20 to Week 48.

    Drug: Vamikibart

  • Experimental
    Arm B

    Participants will receive 4 low-dose vamikibart IVT injections Q4W to Week 12, followed by PRN dosing from Week 20 to Week 48.

    Drug: Vamikibart

  • Sham comparator
    Arm C

    Participants will receive 4 sham injections Q4W to Week 12, followed by PRN sham dosing from Week 20 to Week 48.

    Other: Sham

Interventions

  • Participants will receive vamikibart IVT injection

    Also known as: RO7200220

  • OtherSham

    Participants will receive a sham procedure that mimics an IVT injection.

06

What researchers measure

Primary outcomes

  1. Proportion of participants with ≥ 15 letter improvement from baseline in best-corrected visual acuity (BCVA) at Week 16

    Time frame: Week 16

Secondary outcomes

  1. Proportion of participants with ≥ 15 letter improvement from baseline in BCVA at Week 20

    Time frame: Week 20

  2. Change from baseline in BCVA at Week 16

    Time frame: Week 16

  3. Change from baseline in central subfield thickness (CST) at Week 16

    Time frame: Week 16

  4. Change from Baseline in BCVA at Weeks 20 and 52

    Time frame: Weeks 20 and 52

  5. Change from baseline in CST at Weeks 20 and 52

    Time frame: Weeks 20 and 52

  6. Proportion of participants with uveitic macular edema secondary to non-infectious uveitis (UME) resolution defined by standardized (by machine) CST threshold <325um on optical coherence tomography (OCT) from baseline at Weeks 16 and 52

    Time frame: Weeks 16 and 52

  7. Time to rescue treatment

    Time frame: Up to Week 52

  8. Number of rescue treatments received

    Time frame: Up to Week 52

  9. Type of rescue treatments received

    Time frame: Up to Week 52

  10. Proportion of participants with ≥15 letter improvement from baseline in BCVA at Week 16 and 52

    Time frame: Weeks 16 and 52

  11. Proportion of participants without ≥15 letter loss from baseline in BCVA at Week 16 and 52

    Time frame: Weeks 16 and 52

  12. Number of PRN injections received

    Time frame: Up to Week 52

  13. Time to first PRN injection

    Time frame: Up to Week 52

  14. Change from baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) at Weeks 16 and 52

    Time frame: Weeks 16 and 52

  15. Percentage of participants with ocular adverse events (AEs)

    Time frame: Up to Week 52

  16. Percentage of participants with non-ocular AEs

    Time frame: Up to Week 52

  17. Percent change from baseline in corneal endothelial cell density at Week 24

    Time frame: Week 24

  18. Percentage of participants with adverse events of special interest (AESIs)

    Time frame: Up to Week 52

  19. Percent change from baseline in corneal endothelial cell density at Week 52

    Time frame: Week 52

  20. Aqueous humor (AH) concentration of vamikibart

    Time frame: Up to Week 52

  21. Serum concentration of vamikibart

    Time frame: Up to Week 52

  22. Anti-drug antibody titer to vamikibart

    Time frame: Baseline to Week 52

07

Study locations

77 sites
  • Kaiser Permanente Southern California
    Los Angeles, California 90027, United States
  • Colorado Retina Associates, PC
    Lakewood, Colorado 80228, United States
  • Retina Vitreous Associates of Florida
    St. Petersburg, Florida 33711-1141, United States
  • Cumberland Valley Retina PC
    Hagerstown, Maryland 21740, United States
  • VitreoRetinal Surgery, PLLC.
    Minneapolis, Minnesota 55435, United States
  • Truhlsen Eye Institute
    Omaha, Nebraska 68106-5540, United States
  • Envision Ocular, LLC
    Bloomfield, New Jersey 07003, United States
  • Wake Forest Baptist Health Eye Centre
    Winston-Salem, North Carolina 27157, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • The Ohio State University Investigational Drug Services
    Columbus, Ohio 43212, United States
  • Oregon Health & Science Uni
    Portland, Oregon 97239, United States
  • Erie Retina Research
    Erie, Pennsylvania 16507-1429, United States
  • Palmetto Retina Center
    West Columbia, South Carolina 29169, United States
  • Tennessee Retina PC
    Nashville, Tennessee 37203, United States
  • Austin Clinical Research LLC
    Austin, Texas 78750, United States
  • Texas Retina Associates
    Dallas, Texas 75231, United States
  • LKH-Univ.Klinikum Graz
    Graz, 8036, Austria
  • Kepler Universitätskliniken GmbH - Med Campus III
    Linz, 4021, Austria
  • Medizinische Universitat Wien
    Vienna, 1090, Austria
  • Retina Clinic
    São Paulo, São Paulo 01427-002, Brazil
  • Universidade Federal de Sao Paulo - UNIFESPX
    São Paulo, São Paulo 04023-062, Brazil
  • CEMAPE - Centro Médico
    São Paulo, São Paulo 04084-002, Brazil
  • Fiocruz - Fundação Oswaldo Cruz
    Rio de Janeiro, 21040-360, Brazil
  • Kensington Vision and Research Centre
    Toronto, Ontario M5T 3A9, Canada
  • Hôpital Maisonneuve - Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • CHU de Quebec-Universite Laval
    Québec, G1S 4L8, Canada
  • Peking Union Medical College Hospital
    Beijing, 100032, China
  • Beijing Tongren Hospital
    Beijing, 100730, China
  • The Second Hospital of Jilin University
    Changchun, 130041, China
  • The First Affiliated Hospital, Chongqing Medical University
    Chongqing, 400016, China
  • Zhongshan Ophthalmic Center, Sun Yat-sen University
    Guangzhou, 510060, China
  • Second Affiliated Hospital Zhejiang University College of Medicine
    Hangzhou, China
  • Shanghai First People's Hospital
    Shanghai, 200080, China
  • Tianjin Medical University Eye Hospital
    Tianjin, 300070, China
  • Eye Hospital, Wenzhou Medical University
    Wenzhou, 325027, China
  • Ren Min Hospital Affiliated Wu Han University
    Wuhan, 430060, China
  • Rambam Medical Center
    Haifa, 3109601, Israel
  • Hadassah MC
    Jerusalem, 9112001, Israel
  • Meir Medical Center
    Kfar Saba, 4428164, Israel
  • Rabin MC
    Petah Tikva, 4941492, Israel
  • Kaplan Medical Center
    Rehovot, 7660101, Israel
  • Tel Aviv Sourasky MC
    Tel Aviv, 6423906, Israel
  • Assuta Hashalom Medical Center
    Tel Aviv, 6789140, Israel
  • AUSL ? IRCCS Santa Maria Nuova
    Reggio Emilia, Emilia-Romagna 42100, Italy
  • ASL 4 SSR Ospedale Santa Maria di Montallegro
    Rapallo, Liguria 16035, Italy
  • Irccs Ospedale San Raffaele
    Milan, Lombardy 20132, Italy
  • Asst Fatebenefratelli Sacco
    Milan, Lombardy 20157, Italy
  • Hospital de la Ceguera APEC
    Mexico City, Mexico CITY (federal District) 04030, Mexico
  • Het Oogziekenhuis Rotterdam
    Rotterdam, 3011 BH, Netherlands
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584 CX, Netherlands
  • OFTALMIKA Sp. z o.o
    Bydgoszcz, 85-631, Poland
  • Gabinet Okulistyczny Prof Edward Wylegala
    Katowice, 40-594, Poland
  • SP ZOZ Szpital Uniwersytecki w Krakowie Oddzia? Kliniczny Okulistyki i Onkologii Okulistycznej
    Krakow, 31-501, Poland
  • SPSK nr 1 w Lublinie
    Lublin, 20-079, Poland
  • SPEKTRUM Osrodek Okulistyki Klinicznej
    Wroclaw, 53-334, Poland
  • AIBILI - Association for Innovation and Biomedical Research on Light
    Coimbra, 3000-548, Portugal
  • Instituto de Oftalmologia Dr. Gama Pinto
    Lisbon, 1169-019, Portugal
  • Hospital de Santa Maria
    Lisbon, 1649-035, Portugal
  • Pusan National University Hospital
    Busan, 49241, South Korea
  • Yeungnam University Medical Center
    Daegu, 42415, South Korea
  • Ajou University Medical Center
    Gyeonggi-do, 16499, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, 13605, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Seoul St Mary's Hospital
    Seoul, 06591, South Korea
  • Kim's Eye Hospital
    Seoul, 07301, South Korea
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Mackay Memorial Hospital
    Taipei, Taiwan
  • Chang Gung Medical Foundation - Linkou
    Taoyuan, 333, Taiwan
  • Queen Elizabeth Hospital
    Birmingham, B15 2TH, United Kingdom
  • Bradford Royal Infirmary
    Bradford, BD9 6RJ, United Kingdom
  • Bristol Eye Hospital
    Bristol, BS1 2LX, United Kingdom
  • Gloucestershire Hospitals NHS Foundation Trust
    Gloucestershire, GL1 3NN, United Kingdom
  • Royal Liverpool University Hospital
    Liverpool, L7 8XP, United Kingdom
  • Western Eye Hospital
    London, NW1 5QH, United Kingdom
  • James Cook Hospital
    Middlesbrough, TS4 3BW, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Dec 2024, 23 months.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 23 months is close to that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2022
First posted
Dec 8, 2022
StartActual
Jan 9, 2023
Primary completionActual
Dec 9, 2024
CompletionActual
Jul 9, 2025
Results delay requested
Nov 19, 2025
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05642312
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 8, 2022
Start date
Jan 9, 2023
Primary completion
Dec 9, 2024
Completion
Jul 9, 2025
Last update
Nov 21, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vamikibart

Start the discussion